The UK government dedicates £5.5 million towards establishing a Medicines Manufacturing Skills Centre of Excellence. This center aims to bolster the pool of skilled individuals in the UK’s life sciences sector, fostering innovation and enabling the country to respond to future health crises effectively. It will leverage existing infrastructure and industry best practices to provide sustainable, comprehensive training opportunities.
Improving Expertise in Pharmaceutical Manufacturing
Sarah Goulding, Executive Director for Healthy Living and Agriculture Domain at Innovate UK, emphasized the critical role of talent and skills in driving innovation and industry growth. She asserted that this investment would fortify the UK’s pharmaceutical manufacturing skills and training ecosystem, positively impacting the talent pool and skill development for innovation in UK businesses.
This recent funding announcement is part of the £650 million ‘Life Sci for Growth’ funding initiative launched in May 2023, which includes £48 million allocated for scientific innovation to prepare the UK for potential future health emergencies, among other policies.
Significance of the New Medicines Manufacturing Center for the Life Sciences Sector
George Freeman, MP, Minister of State at the Department for Science for Innovation and Technology, emphasized the necessity of having a world-class workforce to keep the sector competitive globally. He underscored that a center of excellence, through investment in talent attraction, retention, and development across the UK, would enhance the UK’s reputation as the premier global hub for innovative medicines manufacturing.
Steve Bates OBE, Chief Executive Officer of the UK BioIndustry Association, echoed this sentiment, highlighting that an investment in a center of excellence would contribute to the UK’s global leadership in cutting-edge medicines manufacturing.
In late August 2023, another round of funding was also announced to boost the UK medicines manufacturing sector further and promote innovation in the biopharma industry.
